Literature DB >> 29621601

Results from the third Scottish National Prevalence Survey: is a population health approach now needed to prevent healthcare-associated infections?

S Cairns1, C Gibbons2, A Milne2, H King2, M Llano2, L MacDonald2, W Malcolm2, C Robertson3, J Sneddon4, J Weir2, J Reilly5.   

Abstract

BACKGROUND: Healthcare-associated infections (HCAIs) are a major public health concern and a significant cause of morbidity and mortality. A robust and current evidence base that is specific to local, national and Europe-wide settings is necessary to inform the development of strategies to reduce HCAI and contain antimicrobial resistance. AIM: To measure the prevalence of HCAI and antimicrobial prescribing and identify key priority areas for interventions to reduce the burden of infection.
METHODS: A national rolling point-prevalence survey (PPS) in National Health Service (NHS) acute, NHS non-acute, NHS paediatric, and independent hospitals was carried out between September and November 2016 using the European Centre for Disease Prevention and Control protocol designed for the European PPS.
FINDINGS: The prevalence of HCAI was 4.6%, 2.7%, and 3.2% in acute adults, paediatric and non-acute patient groups, respectively. The most frequent HCAI types reported in adult patients were urinary tract infection and pneumonia. The prevalence of antimicrobial prescribing was 35.7%, 29.3%, and 13.8% in acute adults, paediatric, and non-acute patient groups, respectively. Respiratory, skin and soft tissue, gastrointestinal, and urinary tract infections were the most common infections being treated at the time of survey.
CONCLUSION: HCAI continues to be a public health concern in Scotland. Urinary tract infection and pneumonia continue to place a significant burden on patients and on healthcare delivery, including those that develop in the community and require hospital admission. A broader population health approach which focuses on reducing the risk of infection upstream would reduce these infections in both community and hospital settings. Crown
Copyright © 2018. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Epidemiology; Healthcare-associated infection; Infection prevention and control; Pneumonia; Point prevalence surveys; Urinary tract infection

Mesh:

Substances:

Year:  2018        PMID: 29621601     DOI: 10.1016/j.jhin.2018.03.038

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  5 in total

1.  Burden of five healthcare associated infections in Australia.

Authors:  P L Russo; A J Stewardson; M J Lydeamore; B G Mitchell; T Bucknall; A C Cheng
Journal:  Antimicrob Resist Infect Control       Date:  2022-05-13       Impact factor: 6.454

2.  Establishing the prevalence of healthcare-associated infections in Australian hospitals: protocol for the Comprehensive Healthcare Associated Infection National Surveillance (CHAINS) study.

Authors:  Philip L Russo; Andrew Stewardson; Allen C Cheng; Tracey Bucknall; Kalisvar Marimuthu; Brett G Mitchell
Journal:  BMJ Open       Date:  2018-11-08       Impact factor: 2.692

3.  The prevalence of healthcare associated infections among adult inpatients at nineteen large Australian acute-care public hospitals: a point prevalence survey.

Authors:  Philip L Russo; Andrew J Stewardson; Allen C Cheng; Tracey Bucknall; Brett G Mitchell
Journal:  Antimicrob Resist Infect Control       Date:  2019-07-15       Impact factor: 4.887

4.  Prevalence of Clinical Signs Within Reference Ranges Among Hospitalized Patients Prescribed Antibiotics for Pneumonia.

Authors:  Michael Klompas; Aileen Ochoa; Wenjing Ji; Caroline McKenna; Roger Clark; Erica S Shenoy; David Hooper; Chanu Rhee
Journal:  JAMA Netw Open       Date:  2020-07-01

5.  Point prevalence survey of antimicrobial use and healthcare-associated infections in Belgian acute care hospitals: results of the Global-PPS and ECDC-PPS 2017.

Authors:  Eline Vandael; Katrien Latour; Herman Goossens; Koen Magerman; Nico Drapier; Boudewijn Catry; Ann Versporten
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-13       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.